Article
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
Current hematologic malignancy reports - 1 Jun 2006
Wadleigh Martha, Gilliland D Gary
Abstract excerpt
A common somatic point mutation has recently been identified in the Janus kinase 2 (JAK2) gene in virtually all cases of polycythemia vera and in a majority of patients with essential thrombocythemia and idiopathic myelofibrosis. This common mutation in the pseudokinase autoinhibitory domain of the enzyme results in constitutive tyrosine kinase activation, which in turn leads to cytokine hypersensitivity and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.